Clinical Trials in San Diego California

Results

Hot

Post your clinical trial on JoinClinicalTrials.com

Ellijay, Georgia 30536
United States

Post your clinical trial on JoinClinicalTrials.com to reach thousands of viewer daily. Our Clinical Trial Listings have consistently proven to be an ...

Results 1 - 1 of 1

Effects of Fresh Mango Pulp Consumption on Satiety and Cardiometabolic Health
NCT03957928
Condition: Satiety
Interventions: Other: Low fat cookie; Other: Mango fruit
Sponsor: San Diego State University
Recruiting
Effects of Snack Types on Acute Glucose and Insulin Response
NCT03956602
Condition: Satiety
Interventions: Other: Pretzels; Other: Brazil nuts; Other: Potato chips; Other: Mixed nuts
Sponsor: San Diego State University
Recruiting
Memantine Effects on Sensorimotor Gating and Neurocognition in Schizophrenia
NCT03860597
Conditions: Schizophrenia; Schizo Affective Disorder; Schizoaffective Disorder; Healthy
Interventions: Drug: Memantine; Drug: Placebos
Sponsor: University of California, San Diego
Recruiting
A Safety and Efficacy Study to Evaluate Wound Healing
NCT03639883
Condition: Wound Heal
Intervention: Drug: AIV001
Sponsor: Aiviva BioPharma Inc.
Recruiting
Amphetamine Effects on EEG Biomarkers of Reward and Motivation
NCT03616717
Condition: Healthy Adults
Interventions: Drug: dextroamphetamine; Drug: placebo
Sponsor: University of California, San Diego
Recruiting
The Pride Body Project
NCT03451513
Conditions: Eating Disorder; Body Image
Interventions: Behavioral: Pride Body Project; Behavioral: Media Advocacy
Sponsors: San Diego State University; National Institute on Minority Health and Health Disparities (NIMHD)
Recruiting
Integrated Eye Tracking and Neural Monitoring for TBI: Optimization
NCT03451058
Condition: Traumatic Brain Injury
Intervention:
Sponsors: United States Naval Medical Center, San Diego; Uniformed Services University of the Health Sciences; The Defense and Veterans Brain Injury Center
Recruiting
Effects of Fresh Watermelon Consumption on Satiety and Cardiometabolic Health
NCT03380221
Condition: Satiety
Interventions: Other: Watermelon; Other: Low fat cookies
Sponsor: San Diego State University
Recruiting
Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness
NCT03380195
Condition: Heart Rate Recovery
Interventions: Other: Watermelon juice; Other: Sport drink; Other: Sugar water; Other: Water
Sponsor: San Diego State University
Recruiting
Effects of Mixed Nut Consumption on Satiety and Weight Management
NCT03375866
Condition: Satiety
Interventions: Other: Pretzels; Other: Mixed nuts
Sponsor: San Diego State University
Recruiting
Cognitive Training for PTSD
NCT03316196
Condition: Posttraumatic Stress Disorder
Interventions: Behavioral: COGENT COGNITIVE TRAINING; Behavioral: Non training computer condition
Sponsor: VA Office of Research and Development
Recruiting
Managing MTBI-related Headaches With rTMS
NCT03314584
Condition: Traumatic Brain Injury (TBI)
Interventions: Device: Transcranial Magnetic Stimulation; Device: Sham Transcranial Magnetic Stimulation
Sponsor: VA Office of Research and Development
Recruiting
Enhancement of PTSD Treatment With Computerized Executive Function Training
NCT03260127
Condition: Posttraumatic Stress Disorder
Interventions: Behavioral: Computerized executive function training plus CPT (CEFT-CPT); Behavioral: Word game training plus CPT (WT-CPT)
Sponsor: VA Office of Research and Development
Recruiting
Transcranial Electrical Stimulation for mTBI
NCT03244475
Conditions: Mild Traumatic Brain Injury (mTBI); Post-traumatic Stress Disorder
Interventions: Device: IASIS Micro Current Neurofeedback; Device: Nexalin
Sponsors: VA Office of Research and Development; San Diego Veterans Healthcare System
Recruiting
Neural Bases of Multiple Forms of Self-regulatory Control in Bulimia Nervosa
NCT02997475
Condition: Bulimia Nervosa
Intervention:
Sponsors: University of California, San Diego; National Institute of Mental Health (NIMH); The Hilda & Preston Davis Foundation
Recruiting
CBT-I for Veterans With TBI
NCT02658669
Conditions: Insomnia; Traumatic Brain Injury
Interventions: Behavioral: Cognitive-Behavioral Therapy for Insomnia; Behavioral: Sleep Education
Sponsor: VA Office of Research and Development
Recruiting
Pharmacologically-augmented Cognitive Therapies (PACTs) for Schizophrenia.
NCT02634684
Condition: Schizophrenia
Interventions: Drug: Dextroamphetamine; Drug: Placebo
Sponsor: University of California, San Diego
Recruiting
Video Education for Prenatal Testing Choices
NCT04062968
Condition: Pregnancy
Intervention: Other: Video education
Sponsor: United States Naval Medical Center, San Diego
Recruiting
Safety and Efficacy of Deoxycholic Acid Injection for Reduction of Upper Inner Thigh Fat
NCT04054011
Condition: Adiposity
Intervention: Drug: Deoxycholic Acid
Sponsor: University of California, San Diego
Recruiting
Transmembrane Electromyography (TM-EMG) for the Assessment of Neuromuscular Function in the Oropharynx
NCT03986671
Conditions: Obstructive Sleep Apnea; Amyotrophic Lateral Sclerosis; Muscular Dystrophies; Healthy
Intervention: Device: Transmembrane EMG Oropharynx Probe
Sponsor: Powell Mansfield Inc.
Recruiting
TNP-2092 to Treat Acute Bacterial Skin and Skin Structure Infection
NCT03964493
Conditions: Skin and Subcutaneous Tissue Bacterial Infections; Gram-Positive Bacterial Infections
Interventions: Drug: TNP-2092; Drug: Vancomycin
Sponsor: TenNor Therapeutics Limited
Recruiting
Treatment of Perianal Disease Using Adipose-derived Stem Cells
NCT03913572
Conditions: Perianal Fistula; Crohn Disease
Intervention: Procedure: Injection of adipose-derived stem cells into perianal fistula
Sponsor: University of California, San Diego
Recruiting
Recurrence Monitoring in NSCLC Using Circulating Tumor DNA
NCT03878537
Condition: Non Small Cell Lung Cancer
Intervention:
Sponsors: Scripps Translational Science Institute; Scripps Health; Lexent Bio, Inc.
Recruiting
Urinary Stress Incontinence and Urgency in Women With EMSELLA
NCT03877640
Conditions: Stress Urinary Incontinence; Urge Incontinence
Intervention: Device: BTL EMSELLA
Sponsor: San Diego Sexual Medicine
Recruiting
Vagal Nerve Stimulation to Probe Inflammation and Brain in Post-traumatic Stress
NCT03858985
Condition: Post-traumatic Stress
Interventions: Device: Cervical Transcutaneous Vagus Nerve Stimulation (Active Comparator); Device: Cervical Transcutaneous Vagus Nerve Stimulation (Sham Comparator)
Sponsor: VA Office of Research and Development
Recruiting
Evaluation of an Incentive-based Intervention to Improve 90-day Adherence in PAP-Naive Patients
NCT03851094
Condition: Obstructive Sleep Apnea
Intervention: Behavioral: Wellth app
Sponsors: ResMed; Wellth Inc.
Recruiting
Fractional Radiofrequency for the Treatment and Reduction of Facial Wrinkles
NCT03776461
Conditions: Rhytides; Wrinkle
Intervention: Device: Venus Viva
Sponsor: Venus Concept
Recruiting
Restylane Silk Microinjections to Cheeks
NCT03742479
Condition: Wrinkle
Intervention: Device: Restylane® Silk
Sponsor: Goldman, Butterwick, Fitzpatrick and Groff
Recruiting
Biomarker Predictors of Memantine Sensitivity in Patients With Alzheimer's Disease
NCT03703856
Condition: Alzheimer Disease
Interventions: Drug: Memantine; Drug: Placebo
Sponsor: University of California, San Diego
Recruiting
Acceptance and Commitment Therapy for Aging People Living With HIV in Chronic Pain
NCT03699020
Conditions: HIV/AIDS; Chronic Pain
Interventions: Behavioral: Acceptance and Commitment Therapy (ACT); Other: Chronic Pain Education
Sponsors: University of California, San Diego; National Institute on Aging (NIA)
Recruiting
Evaluation of an Open-source Speech-processing Platform
NCT03686046
Condition: Hearing Loss, Sensorineural
Intervention: Other: Exploratory use
Sponsors: San Diego State University; University of California, San Diego
Recruiting
Low-dose CT-based Method for Detection of Subclinical Anthracycline-induced Cardiotoxicity
NCT03553654
Condition: Neoplasms
Intervention: Diagnostic Test: low dose CT
Sponsor: University of California, San Diego
Recruiting
Self-Management of Continuous Positive Airway Pressure Settings
NCT03536572
Condition: Obstructive Sleep Apnea
Intervention: Behavioral: Sleep Apnea Self-Management Program
Sponsor: VA Office of Research and Development
Recruiting
Cannabidiol and Prolonged Exposure
NCT03518801
Condition: PTSD
Interventions: Behavioral: Prolonged Exposure; Drug: Cannabidiol; Drug: placebo
Sponsors: VA Office of Research and Development; University of California, San Diego
Recruiting
Yoga and Physical Activity for Veterans
NCT03509909
Condition: PTSD
Interventions: Behavioral: Hatha yoga; Behavioral: Supportive physical activity
Sponsor: VA Office of Research and Development
Recruiting
Micro-injections of Transparent Hyaluronic Acid Gel (Restylane® Silk) for Rejuvenation of the Aging Cheek
NCT03461198
Condition: Wrinkle
Intervention: Device: Restylane® Silk
Sponsor: Goldman, Butterwick, Fitzpatrick and Groff
Recruiting
Prospective Pilot Feasibility Study Comparing Envarsus Once-a-day to Tacrolimus Twice-a-day Immunosuppressive Regimen on Drug Bioavailability in Hispanic First Time Kidney Transplant Recipients
NCT03438773
Conditions: Kidney Transplant; Complications; Kidney Transplant Failure and Rejection
Interventions: Drug: Envarsus; Drug: Tacrolimus
Sponsors: California Institute of Renal Research; Balboa Institute of Transplantation; University of California, San Diego
Recruiting
Clinical Trial of Anti-oxidant Astaxanthin in Insulin-resistant Subjects
NCT03310359
Condition: Metabolic Syndrome X
Interventions: Dietary Supplement: Astaxanthin; Other: Placebo
Sponsor: University of California, San Diego
Recruiting
Trial of Surf and Hike Therapy for Major Depressive Disorder
NCT03302611
Condition: Major Depressive Disorder
Intervention: Behavioral: Physical Activity-based Interventions
Sponsors: United States Naval Medical Center, San Diego; Naval Health Research Center
Recruiting
A Prospective Trial of Behavioral Therapy for Chronic Cough
NCT03235466
Condition: Cough
Interventions: Behavioral: Voice Therapy; Behavioral: Voice Therapy and Heart Rate Variability Biofeedback; Behavioral: Heart Rate Variability Biofeedback
Sponsor: University of California, San Diego
Recruiting
Topiramate and Prolonged Exposure
NCT03176953
Condition: PTSD and Alcohol Use Disorder
Interventions: Drug: topiramate; Behavioral: prolonged exposure; Drug: placebo
Sponsors: VA Office of Research and Development; University of California, San Diego
Recruiting
iSTEP - an mHealth Physical Activity and Diet Intervention for Persons With HIV
NCT03123731
Condition: HIV/AIDS
Interventions: Behavioral: Control Arm; Behavioral: iSTEP
Sponsor: University of California, San Diego
Recruiting
The Pathogenesis of OSA in People Living With HIV
NCT03064204
Conditions: Obstructive Sleep Apnea; HIV/AIDS
Intervention:
Sponsors: University of California, San Diego; Center For AIDS Research Creative and Novel Ideas in HIV Research (CFAR CNIHR)
Recruiting
Improving Functions in Veterans With Post-traumatic Peripheral Neuropathic Pain
NCT02979925
Condition: Neuropathic Pain
Interventions: Device: Active Transcutaneous Magnetic Stimulation; Device: Sham Transcutaneous Magnetic Stimulation
Sponsor: VA Office of Research and Development
Recruiting
Behavioral Activation + Cognitive Processing Therapy for PTSD and Comorbid MDD
NCT02874131
Conditions: Posttraumatic Stress Disorder; Major Depressive Disorder
Interventions: Behavioral: Behavioral Activation; Behavioral: Cognitive Processing Therapy
Sponsors: United States Naval Medical Center, San Diego; Naval Health Research Center
Recruiting
Digital Health Feedback System for Longitudinal Measurement of Medication Adherence During Initial ARV Therapy
NCT02800655
Condition: HIV
Intervention: Device: Digital Health Feedback System
Sponsors: University of California, San Diego; National Institute of Mental Health (NIMH); Gilead Sciences; ViiV Healthcare; GlaxoSmithKline; Proteus Digital Health, Inc.
Recruiting
Integrated CBT-I and PE on Sleep and PTSD Outcomes (Impact Study)
NCT02774642
Conditions: Posttraumatic Stress Disorders; Chronic Insomnia
Interventions: Behavioral: CBTI-PE; Behavioral: Hygiene-PE
Sponsor: VA Office of Research and Development
Recruiting
Cognitive-Behavioral Conjoint Therapy (CBCT) Project
NCT02720016
Condition: Post Traumatic Stress Disorder
Interventions: Behavioral: CBCT-Home Based (CBCT-HB); Behavioral: CBCT-Office Based (CBCT-OB); Behavioral: PTSD Family Education (PFE)
Sponsor: VA Office of Research and Development
Recruiting
Rehabilitation of Visual Attention Following mTBI
NCT02719964
Condition: Traumatic Brain Injury
Interventions: Other: Visual Attention Program (UCR Games); Other: Speech Pathologist-Directed Therapy; Other: General Cognitive Rehabilitation Games (Lumosity)
Sponsor: United States Naval Medical Center, San Diego
Recruiting
Perturbing of HIV Reservoir With Immune Stimulation
NCT02707692
Conditions: AIDS; HIV
Interventions: Biological: Fluarix; Biological: Pneumovax; Other: Placebo
Sponsors: University of California, San Diego; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting
OTIS Vedolizumab Pregnancy Exposure Registry
NCT02678052
Conditions: Colitis, Ulcerative; Crohn's Disease
Interventions: Drug: Vedolizumab; Biological: Other Biological Agent
Sponsor: Takeda
Recruiting
Pathophysiology of the Upper Airway in Patients With COPD and Concomitant OSA
NCT02567448
Condition: Obstructive Sleep Apnea
Intervention: Other: Sleep and pulmonary physiologic measurements
Sponsor: University of California, San Diego
Recruiting
Efficacy of ART to Interrupt HIV Transmission Networks
NCT02528773
Condition: HIV
Intervention:
Sponsor: University of California, San Diego
Recruiting
Cognitive Rehab and Exposure Treatment for Hoarding
NCT02402647
Condition: Hoarding Disorder
Interventions: Behavioral: CREST; Behavioral: ET
Sponsor: VA Office of Research and Development
Recruiting
Sleep Disordered Breathing in Acute Congestive Heart Failure
NCT03804827
Conditions: Obstructive Sleep Apnea; Heart Failure; With Decompensation
Intervention:
Sponsor: University of California, San Diego
Recruiting
The Use of MMC During PRK and Its Effect on Postoperative Topical Steroid Requirements
NCT02030990
Condition: Corneal Opacity
Interventions: Drug: Mitomycin-C; Drug: Fluorometholone 1% topical ocular steroid
Sponsor: United States Naval Medical Center, San Diego
Recruiting
Cabozantinib in Combination With 13-cis-Retinoic Acid in Children With Relapsed or Refractory Solid Tumors
NCT03611595
Condition: Solid Tumor
Interventions: Drug: Cabozantinib; Drug: 13-cis-retinoic acid
Sponsors: Peter Zage; Exelixis
Recruiting
Improving Office Based Treatment of Opioid Use Disorder With Technology
NCT03586466
Condition: Opioid-use Disorder
Interventions: Device: BupreCare; Drug: Buprenorphine/naloxone; Other: MEMS
Sponsors: MedicaSafe, Inc.; Friends Research Institute, Inc.
Recruiting
Evaluating the Use of Peer Specialists to Deliver Cognitive Behavioral Social Skills Training
NCT03467243
Condition: Serious Mental Illness
Interventions: Behavioral: Cognitive Behavioral Social Skills Training; Behavioral: Social Skills Training; Behavioral: Treatment as usual
Sponsor: VA Office of Research and Development
Recruiting
Cognitive Rehabilitation Therapy for Mild Cognitive Impairment
NCT03225482
Condition: Mild Cognitive Impairment
Interventions: Behavioral: Motivationally Enhanced Compensatory Cognitive Training; Behavioral: Goal-focused Supportive Contact
Sponsors: VA Office of Research and Development; Portland VA Medical Center
Recruiting
Self-management of Blood Pressure Medication for Hypertensive Veterans
NCT03224624
Condition: Hypertension
Intervention: Other: self-management protocol for hypertension care
Sponsor: VA Office of Research and Development
Recruiting
Text Messaging to Engage and Retain Veterans in Smoking Cessation Counseling
NCT03177265
Condition: Nicotine Dependence
Interventions: Behavioral: Text messaging prior to first counseling call; Behavioral: Text-to-Enhance; Behavioral: Mail Notice; Behavioral: Telephone Counseling
Sponsor: VA Office of Research and Development
Recruiting
Directed Use of REmote Patient Management System AMia to Achieve Prescribed Dry Weight
NCT04002440
Conditions: Efficacy; Safety Issues
Interventions: Combination Product: AMIA with SHARESOURCE Connectivity Platform; Device: HomeChoice PRO
Sponsors: University of California, San Diego; Baxter Healthcare Corporation; Scripps Health; Home Dialysis Therapies of San Diego
Recruiting
HTX-011 Administration Study in Planned Caesarean Section Procedure
NCT03955211
Condition: Analgesia
Interventions: Drug: HTX-011; Device: Luer lock applicator
Sponsor: Heron Therapeutics
Recruiting
Paracervical Block Volume and Pain Control During Dilation and Curettage
NCT03636451
Conditions: Abortion, Spontaneous; Abortion in First Trimester; Pain Uterus
Interventions: Drug: 0.5% Lidocaine; Drug: 1% Lidocaine
Sponsors: University of California, San Diego; Society of Family Planning
Recruiting
Connecting Women to Care: Home-based Psychotherapy for Women With MST Living in Rural Areas
NCT03429166
Condition: PTSD
Interventions: Behavioral: STAIR; Behavioral: PCT
Sponsors: VA Office of Research and Development; San Diego Veterans Healthcare System
Recruiting
Trial to Reduce Sitting Time in Postmenopausal Latina Women at Increased Risk for Heart Disease
NCT02905929
Condition: Sedentary Lifestyle
Interventions: Device: ActivPAL inclinometer; Behavioral: Phone counseling call: Breaking up sitting time; Behavioral: In-person counseling: Breaking up sitting time; Behavioral: Phone counseling call: Healthy living; Other: Tools to prompt standing; Behavioral: In-person counseling: Healthy living
Sponsors: University of California, San Diego; South Bay Latino Research Center; San Ysidro Health Center; San Diego State University
Recruiting
Abatacept for SLE Arthritis (IM101-330)
NCT02429934
Condition: Systemic Lupus Erythematosus Arthritis
Interventions: Drug: abatacept; Drug: Placebo
Sponsors: University of California, Los Angeles; Bristol-Myers Squibb
Recruiting
Substrate Versus Trigger Ablation for Paroxysmal Atrial Fibrillation
NCT02169037
Condition: Atrial Fibrillation
Interventions: Procedure: FIRM Ablation; Procedure: Conventional AF ablation with PVI
Sponsors: University of California, San Diego; National Institutes of Health (NIH); National Heart, Lung, and Blood Institute (NHLBI)
Recruiting
Validation of Patient Reported Outcome Measures for Use in Vulvodynia
NCT03770169
Condition: Vulvodynia
Intervention:
Sponsor: Ipsen
Recruiting
Characteristics and Inflammatory Markers in Children With Eosinophilic Esophagitis (EoE)
NCT03980886
Condition: Eosinophilic Esophagitis
Intervention:
Sponsors: University of California, San Diego; National Institutes of Health (NIH); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting
Benralizumab Pregnancy Exposure Study
NCT03794999
Condition: Asthma
Interventions: Drug: Benralizumab-exposure; Drug: Exposure to other asthma medications
Sponsors: AstraZeneca; University of California, San Diego, Department of Pediatrics
Recruiting
The Natural History of Danon Disease
NCT03766386
Condition: Danon Disease
Intervention:
Sponsors: University of California, San Diego; Rocket Pharmaceuticals Inc.
Recruiting
Antibiotic Prophylaxis With Routine Ureteral Stent Removal
NCT02944825
Conditions: Urolithiasis; UTI
Interventions: Drug: Ciprofloxacin; Drug: trimethoprim/sulfamethoxazole; Drug: No Intervention
Sponsors: University of California, San Diego; Genesis HealthCare
Recruiting
Rady Children's Institute Genomic Biorepository
NCT02917460
Condition: Genetic Diseases
Intervention: Genetic: Genomic sequencing and molecular diagnostic results, if any
Sponsor: Rady Pediatric Genomics & Systems Medicine Institute
Recruiting
Endourology Disease Group Excellence (EDGE) Consortium: Antibiotics (Abx) for Percutaneous Nephrolithotomy (PCNL) Part 2
NCT02829060
Conditions: Nephrolithiasis; Urinary Tract Infection (UTI); Sepsis
Interventions: Drug: Nitrofurantoin 100 MG, 7d; Drug: Gentamicin, 5mg/kg; Drug: Ampicillin 2g; Drug: Nitrofurantoin 100 mg, 48 hrs; Drug: Gentamicin, 80 mg, 7d; Drug: Gentamicin, 80 mg, 48hr
Sponsor: University of California, San Diego
Recruiting
FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
NCT03841110
Conditions: Advanced Solid Tumors; Lymphoma; Gastric Cancer; Colorectal Cancer; Head and Neck Cancer; Squamous Cell Carcinoma; EGFR Positive Solid Tumor; HER2-positive Breast Cancer; Hepatocellular Carcinoma; Small Cell Lung Cancer; Renal Cell Carcinoma; Pancreas Cancer; Melanoma; NSCLC; Urothelial Carcinoma; Cervical Cancer; Microsatellite Instability; Merkel Cell Carcinoma
Interventions: Drug: FT500; Drug: Nivolumab; Drug: Pembrolizumab; Drug: Atezolizumab; Drug: Cyclophosphamide; Drug: Fludarabine
Sponsor: Fate Therapeutics
Recruiting
Pharmacokinetics of IFX and TNF Concentrations in Serum, Stool, and Colonic Mucosa in Acute Severe Ulcerative Colitis
NCT03765450
Condition: Ulcerative Colitis
Intervention: Drug: Infliximab
Sponsor: Robarts Clinical Trials Inc.
Recruiting
TReatment of Pulmonary Hypertension Group II Study
NCT03611270
Condition: Pulmonary Hypertension (PH) Due to Left Heart Disease
Intervention: Device: Pulmonary Denervation
Sponsor: SoniVie Ltd.
Recruiting
Mentors Offering Maternal Support (M-O-M-S™): A Prenatal Program for Decreasing Maternal Anxiety and Depression
NCT03393637
Conditions: Anxiety Fear; Prenatal Depression; Infant, Low Birth Weight; Preterm Birth; Maternal
Intervention: Behavioral: Mentors Offering Maternal Support (M-O-M-S)
Sponsors: University of the Incarnate Word; Joint Program Committee - 5; 59th Medical Wing Science and Technology; United States Naval Medical Center, San Diego; Madigan Army Medical Center; 711th Human Performance Wing
Recruiting
Remote Sleep Apnea Management
NCT03007745
Conditions: Sleep Apnea - Obstructive; Cost Effectiveness; Telemedicine
Intervention: Device: autoadjusting continuous positive airway pressure
Sponsor: VA Office of Research and Development
Recruiting
Collaborative Care for Women Veterans
NCT02950961
Conditions: Anxiety; Depression; Stress Disorders, Post Traumatic
Intervention: Behavioral: Collaborative Care for Women Veterans
Sponsor: VA Office of Research and Development
Recruiting
Early vs. Interval Postpartum IUD Insertion
NCT03462758
Condition: Contraception
Intervention: Device: IUD
Sponsors: University of California, San Diego; University of New Mexico; United States Naval Medical Center, San Diego
Recruiting
OPEN & ASK: Improving Patient-Centered Communication in Primary Care
NCT03385512
Conditions: Patient Engagement; Physician's Role; Physician-Patient Relations; Patient Activation
Interventions: Behavioral: OPEN High Touch; Behavioral: OPEN High Tech; Behavioral: ASK
Sponsors: University of California, San Diego; Reliant Medical Group; University of Massachusetts, Worcester; Palo Alto Medical Foundation; Patient-Centered Outcomes Research Institute
Recruiting
Study for the Prediction of Active Rejection in Organs Using Donor-derived Cell-free DNA Detection
NCT03984747
Conditions: Kidney Transplant Rejection; Allograft Rejection; Kidney Transplant; Complications
Intervention:
Sponsor: Natera, Inc.
Recruiting
Carfilzomib With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
NCT02187133
Conditions: Lymphoma, Non-Hodgkin; Lymphoma
Interventions: Drug: Carfilzomib; Drug: Bendamustine; Drug: Rituximab
Sponsors: University of California, San Francisco; National Comprehensive Cancer Network
Recruiting
Phase II Trial of Tesamorelin for Cognition in Aging HIV-Infected Persons
NCT02572323
Condition: Mild Cognitive Impairment
Intervention: Drug: Tesamorelin
Sponsors: University of California, San Diego; University of Southern California; Borrego Health - Stonewall Medical Center
Recruiting
Improved Training Program for Fall Prevention of War Fighters
NCT03446131
Condition: Limb Injury
Intervention:
Sponsors: Mayo Clinic; United States Naval Medical Center, San Diego; Walter Reed National Military Medical Center; Brooke Army Medical Center; University of Illinois at Chicago
Recruiting
FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors
NCT03319459
Conditions: HER2 Positive Gastric Cancer; Colorectal Cancer; Head and Neck Squamous Cell Carcinoma; EGFR Positive Solid Tumor; Advanced Solid Tumors; HER2-positive Breast Cancer; Hepatocellular Carcinoma; Small Cell Lung Cancer; Renal Cell Carcinoma; Pancreas Cancer
Interventions: Drug: FATE-NK100; Drug: Cetuximab; Drug: Trastuzumab
Sponsor: Fate Therapeutics
Recruiting
Psychosocial Rehabilitation After Moral Injury and Loss With Adaptive Disclosure
NCT03056157
Conditions: Post-traumatic Stress Disorder; Moral Injury; Traumatic Loss
Interventions: Behavioral: Adaptive Disclosure for Moral Injury and Loss; Behavioral: Present Centered Therapy
Sponsors: VA Office of Research and Development; Minneapolis Veterans Affairs Medical Center; San Francisco Veterans Affairs Medical Center; San Diego Veterans Healthcare System
Recruiting
INdividualized ITI Based on Fviii(ATE) Protection by VWF
NCT03204539
Conditions: Hemophilia A With Inhibitor; Hemophilia A
Intervention: Drug: Wilate
Sponsor: University of California, Davis
Recruiting
Study of Personalized Cancer Therapy to Determine Response and Toxicity
NCT02478931
Condition: Cancer
Intervention:
Sponsor: Razelle Kurzrock, MD
Recruiting
CPX-351 and Enasidenib in Treating Patients With Relapsed Acute Myeloid Leukemia Characterized by IDH2 Mutation
NCT03825796
Conditions: Blasts 5 Percent or More of Bone Marrow Nucleated Cells; IDH2 Gene Mutation; Recurrent Acute Myeloid Leukemia
Interventions: Drug: Enasidenib Mesylate; Drug: Liposome-encapsulated Daunorubicin-Cytarabine
Sponsors: Jonsson Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting
Mature B-Cell Lymphoma And Leukemia Study III
NCT01046825
Condition: Mature B-Cell Lymphoma
Interventions: Drug: COPAD; Drug: COP, COPD M3, CYM; Drug: COP, COPADM8, CYVE
Sponsor: St. Jude Children's Research Hospital
Recruiting
Glucagon Infusion in T1D Patients With Recurrent Severe Hypoglycemia: Effects on Counter-Regulatory Responses
NCT03490942
Conditions: Hypoglycemia Unawareness; Diabetes Mellitus, Type 1
Interventions: Drug: Glucagon; Drug: Placebo
Sponsors: Xeris Pharmaceuticals; Integrated Medical Development
Recruiting
Study of the Safety and Efficacy of Elagolix in Women With Polycystic Ovary Syndrome
NCT03951077
Condition: Polycystic Ovary Syndrome
Interventions: Drug: Elagolix; Drug: Placebo
Sponsor: AbbVie
Recruiting
A Study to Evaluate the Safety and Efficacy of Elagolix for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women
NCT03886220
Condition: Uterine Fibroids
Interventions: Drug: Elagolix; Drug: Placebo
Sponsor: AbbVie
Recruiting
A Study to Evaluate the Safety and Efficacy of BIIB104 in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS)
NCT03745820
Conditions: Cognitive Impairment Associated With Schizophrenia; Schizophrenia
Interventions: Drug: BIIB104; Other: Placebo
Sponsor: Biogen
Recruiting
Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in a Dose-Reduction Paradigm in the Prevention of Relapse in Patients With Schizophrenia
NCT03593213
Condition: Schizophrenia
Interventions: Drug: Cariprazine; Drug: Placebo
Sponsor: Forest Laboratories
Recruiting
SPIRIT 1: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain
NCT03204318
Condition: Endometriosis Related Pain
Interventions: Drug: Relugolix; Drug: Estradiol/norethindrone acetate; Drug: Placebo for E2/NETA; Drug: Placebo for relugolix
Sponsor: Myovant Sciences GmbH
Recruiting
Work Ability in Young Adult Cancer Survivors
NCT03148080
Condition: Cancer Survivor
Interventions: Procedure: Cognitive Assessment; Other: Questionnaire Administration
Sponsors: Wake Forest University Health Sciences; National Cancer Institute (NCI)
Recruiting
Safety and Efficacy Study of DUR-928 Topical Solution in Subjects With Plaque Psoriasis
NCT03837743
Condition: Plaque Psoriasis
Interventions: Drug: DUR-928 Topical Solution; Drug: Vehicle Topical Solution
Sponsors: Therapeutics, Inc.; Durect
Recruiting
Cryoanalgesia to Treat Post-Amputation Phantom Limb Pain: A Department of Defense Funded Multicenter Study
NCT03449667
Condition: Post-Amputation Phantom Limb Pain
Interventions: Device: Cryoneurolysis; Device: Sham Comparator
Sponsors: University of California, San Diego; United States Department of Defense; Department of Outcomes Research, Cleveland Clinic
Recruiting
AMG0103 in Subjects With Chronic Discogenic Lumbar Back Pain
NCT03263611
Condition: Degenerative Disc Disease
Interventions: Drug: Placebo; Drug: AMG0103
Sponsor: AnGes, Inc.
Recruiting
Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer
NCT01766297
Conditions: Breast Cancer; Breast Neoplasm; Breast Tumor; Cancer of the Breast
Intervention: Radiation: Proton Radiotherapy
Sponsor: Proton Collaborative Group
Recruiting
A Study to Assess PV-10 Chemoablation of Cancer of the Liver
NCT00986661
Conditions: Cancer Metastatic to the Liver; Hepatocellular Carcinoma; Metastatic Melanoma; Metastatic Ocular Melanoma; Metastatic Uveal Melanoma; Metastatic Lung Cancer; Metastatic Colon Cancer; Metastatic Colorectal Cancer; Metastatic Breast Cancer; Metastatic Pancreatic Cancer
Intervention: Drug: PV-10 (10% rose bengal disodium)
Sponsor: Provectus Biopharmaceuticals, Inc.
Recruiting
Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer
NCT01492972
Condition: Prostate Cancer
Interventions: Radiation: Radiation; Drug: Androgen Suppression Therapy
Sponsor: Proton Collaborative Group
Recruiting
CPX-351 and Gemtuzumab Ozogamicin in Treating Patients With Relapsed Acute Myeloid Leukemia
NCT03904251
Condition: Acute Myelogenous Leukemia
Interventions: Drug: Gemtuzumab Ozogamicin; Drug: Liposome-encapsulated Daunorubicin-Cytarabine
Sponsors: Jonsson Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting
A Study to Assess the Safety of GRF6019 Infusions in Subjects With Severe Alzheimer's Disease
NCT03765762
Condition: Severe Alzheimer Disease
Interventions: Drug: GRF6019; Other: Placebo
Sponsor: Alkahest, Inc.
Recruiting
Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic Syndrome
NCT02553941
Conditions: Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndrome; Previously Treated Myelodysplastic Syndrome; Refractory Anemia With Excess Blasts in Transformation; Secondary Myelodysplastic Syndrome
Interventions: Drug: Azacitidine; Drug: Ibrutinib
Sponsors: Brian Jonas; Pharmacyclics LLC.
Recruiting
AtRial Cardiopathy and Antithrombotic Drugs In Prevention After Cryptogenic Stroke
NCT03192215
Condition: Stroke
Interventions: Drug: Apixaban; Drug: Aspirin
Sponsors: Columbia University; National Institute of Neurological Disorders and Stroke (NINDS); University of Cincinnati; Medical University of South Carolina; Bristol-Myers Squibb; Pfizer; Roche Pharma AG; Weill Medical College of Cornell University; University of Washington
Recruiting
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men ( TRAVERSE )
NCT03518034
Conditions: Hypogonadism; Cardiovascular Diseases
Interventions: Drug: Testosterone; Drug: Placebo
Sponsors: AbbVie; Acerus Pharmaceuticals Corporation; Allergan Sales, LLC; Endo Pharmaceuticals; Upsher-Smith Laboratories
Recruiting
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
NCT02465060
Conditions: Advanced Malignant Solid Neoplasm; Bladder Carcinoma; Breast Carcinoma; Cervical Carcinoma; Colon Carcinoma; Colorectal Carcinoma; Endometrial Carcinoma; Esophageal Carcinoma; Gastric Carcinoma; Glioma; Head and Neck Carcinoma; Kidney Carcinoma; Liver and Intrahepatic Bile Duct Carcinoma; Lung Carcinoma; Lymphoma; Malignant Uterine Neoplasm; Melanoma; Ovarian Carcinoma; Pancreatic Carcinoma; Plasma Cell Myeloma; Prostate Carcinoma; Rectal Carcinoma; Recurrent Bladder Carcinoma; Recurrent Breast Carcinoma; Recurrent Cervical Carcinoma; Recurrent Colon Carcinoma; Recurrent Colorectal Carcinoma; Recurrent Esophageal Carcinoma; Recurrent Gastric Carcinoma; Recurrent Glioma; Recurrent Head and Neck Carcinoma; Recurrent Liver Carcinoma; Recurrent Lung Carcinoma; Recurrent Lymphoma; Recurrent Malignant Solid Neoplasm; Recurrent Melanoma; Recurrent Ovarian Carcinoma; Recurrent Pancreatic Carcinoma; Recurrent Plasma Cell Myeloma; Recurrent Prostate Carcinoma; Recurrent Rectal Carcinoma; Recurrent Skin Carcinoma; Recurrent Thyroid Gland Carcinoma; Recurrent Uterine Corpus Carcinoma; Refractory Lymphoma; Refractory Malignant Solid Neoplasm; Refractory Plasma Cell Myeloma; Skin Carcinoma; Thyroid Gland Carcinoma; Uterine Corpus Cancer
Interventions: Drug: Adavosertib; Drug: Afatinib; Drug: Afatinib Dimaleate; Drug: Binimetinib; Drug: Capivasertib; Drug: Copanlisib; Drug: Copanlisib Hydrochloride; Drug: Crizotinib; Other: Cytology Specimen Collection Procedure; Drug: Dabrafenib; Drug: Dabrafenib Mesylate; Drug: Dasatinib; Drug: Defactinib; Drug: Defactinib Hydrochloride; Drug: Erdafitinib; Drug: FGFR Inhibitor AZD4547; Drug: Ipatasertib; Other: Laboratory Biomarker Analysis; Drug: Larotrectinib; Drug: Larotrectinib Sulfate; Biological: Nivolumab; Drug: Osimertinib; Drug: Palbociclib; Biological: Pertuzumab; Drug: PI3K-beta Inhibitor GSK2636771; Drug: Sapanisertib; Drug: Sunitinib Malate; Drug: Taselisib; Drug: Trametinib; Biological: Trastuzumab; Biological: Trastuzumab Emtansine; Drug: Ulixertinib; Drug: Vismodegib
Sponsor: National Cancer Institute (NCI)
Recruiting
Study for Participants With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase II/III Studies
NCT02118584
Condition: Ulcerative Colitis
Intervention: Drug: Etrolizumab
Sponsor: Hoffmann-La Roche
Recruiting
A Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer
NCT03148795
Condition: Prostate Cancer
Intervention: Drug: Talazoparib
Sponsors: Pfizer; Medivation, Inc.
Recruiting
AURORA: Phase 3 Study for the Efficacy and Safety of CVC for the Treatment of Liver Fibrosis in Adults With NASH
NCT03028740
Condition: Nonalcoholic Steatohepatitis
Interventions: Drug: Cenicriviroc; Drug: Placebo
Sponsor: Tobira Therapeutics, Inc.
Recruiting
Breast Cancer WEight Loss Study (BWEL Study)
NCT02750826
Condition: Breast Carcinoma
Interventions: Other: Health Education Program; Other: Weight Loss Intervention
Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI); Division of Cancer Control; NIH Biomarker, Imaging and Quality of Life Studies Funding Program (BIQSFP); Canadian Cancer Trials Group
Recruiting
Safety Follow-up Study in Subjects With Silicone Gel-filled Breast Implants as Compared Both to Saline-filled Breast Implants and to National Norms
NCT00443274
Condition: Breast Implant
Interventions: Other: NBIR Placeholder; Device: 410 Arm; Device: BIFs
Sponsor: Allergan
Recruiting
To Study Generic Calcipotriene and Betamethasone Dipropionate Topical Foam, 0.005%/0.064%, in the Treatment of Psoriasis Vulgaris (Plaque Psoriasis).
NCT03731091
Condition: Psoriasis Vulgaris
Interventions: Drug: Calcipotriene/ betamethasone dipropionate topical foam, 0.005%/0.064%; Drug: Enstilar® foam (LEO Pharma Inc.); Other: Placebo of Calcipotriene/ betamethasone dipropionate topical foam
Sponsor: Glenmark Pharmaceuticals Ltd. India
Recruiting
Long-Term Safety Study Of Tofacinib In Patients With Juvenile Idiopathic Arthritis
NCT01500551
Condition: Juvenile Idiopathic Arthritis
Intervention: Drug: Tofacitinib
Sponsor: Pfizer
Recruiting
An Active and Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Ulcerative Colitis [EXPEDITION]
NCT03616821
Conditions: Colitis; Ulcerative; IBD
Interventions: Drug: Brazikumab; Drug: Vedolizumab; Drug: Placebo
Sponsor: Allergan
Recruiting
An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo and a Currently Available Treatment in Participants With Moderate-to-Severe Plaque Psoriasis
NCT03611751
Condition: Psoriasis
Interventions: Drug: BMS-986165; Other: Placebo; Drug: Apremilast
Sponsor: Bristol-Myers Squibb
Recruiting
Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome
NCT03473223
Condition: Acute Coronary Syndrome
Interventions: Biological: Apolipoprotein A-I [human] (apoA-I); Other: Placebo
Sponsor: CSL Behring
Recruiting
Study to Compare Oral PF-06651600, PF-06700841 and Placebo in Subjects With Moderate to Severe Ulcerative Colitis
NCT02958865
Condition: Ulcerative Colitis
Interventions: Drug: PF-06651600 or Placebo; Drug: PF-06700841 or Placebo; Drug: PF-06700841; Drug: PF-06651600
Sponsor: Pfizer
Recruiting
Aspirin in Preventing Recurrence of Cancer in Patients With HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation Therapy
NCT02927249
Condition: Node Positive HER2 Negative Breast Cancer
Interventions: Other: Placebo; Drug: Aspirin
Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI); United States Department of Defense; Bayer; Canadian Cancer Trials Group
Recruiting
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
NCT02834013
Conditions: Acinar Cell Carcinoma; Adenoid Cystic Carcinoma; Adrenal Cortex Carcinoma; Adrenal Gland Pheochromocytoma; Anal Canal Neuroendocrine Carcinoma; Anal Canal Undifferentiated Carcinoma; Angiosarcoma; Apocrine Neoplasm; Appendix Mucinous Adenocarcinoma; Bartholin Gland Transitional Cell Carcinoma; Basal Cell Carcinoma; Bladder Adenocarcinoma; Cervical Adenocarcinoma; Cervical Clear Cell Adenocarcinoma; Cholangiocarcinoma; Chordoma; Colorectal Squamous Cell Carcinoma; Desmoid-Type Fibromatosis; Endometrial Transitional Cell Carcinoma; Endometrioid Adenocarcinoma; Esophageal Neuroendocrine Carcinoma; Esophageal Undifferentiated Carcinoma; Extrahepatic Bile Duct Carcinoma; Extramammary Paget Disease; Fallopian Tube Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Fibromyxoid Tumor; Gallbladder Carcinoma; Gastric Neuroendocrine Carcinoma; Gastric Squamous Cell Carcinoma; Gastric Undifferentiated Carcinoma; Gastrointestinal Stromal Tumor; Gestational Trophoblastic Tumor; Giant Cell Carcinoma; Intestinal Neuroendocrine Carcinoma; Intrahepatic Cholangiocarcinoma; Lung Carcinoid Tumor; Lung Sarcomatoid Carcinoma; Major Salivary Gland Carcinoma; Malignant Odontogenic Neoplasm; Malignant Peripheral Nerve Sheath Tumor; Malignant Testicular Sex Cord-Stromal Tumor; Metaplastic Breast Carcinoma; Metastatic Malignant Neoplasm of Unknown Primary; Minimally Invasive Lung Adenocarcinoma; Mixed Mesodermal (Mullerian) Tumor; Mucinous Adenocarcinoma; Mucinous Cystadenocarcinoma; Nasal Cavity Adenocarcinoma; Nasal Cavity Carcinoma; Nasopharyngeal Carcinoma; Nasopharyngeal Papillary Adenocarcinoma; Nasopharyngeal Undifferentiated Carcinoma; Oral Cavity Carcinoma; Oropharyngeal Undifferentiated Carcinoma; Ovarian Adenocarcinoma; Ovarian Clear Cell Adenocarcinoma; Ovarian Germ Cell Tumor; Ovarian Mucinous Adenocarcinoma; Ovarian Squamous Cell Carcinoma; Ovarian Transitional Cell Carcinoma; Pancreatic Acinar Cell Carcinoma; Pancreatic Neuroendocrine Carcinoma; Paraganglioma; Paranasal Sinus Adenocarcinoma; Paranasal Sinus Carcinoma; Parathyroid Gland Carcinoma; PEComa; Peritoneal Mesothelioma; Pituitary Gland Carcinoma; Placental Choriocarcinoma; Primary Peritoneal High Grade Serous Adenocarcinoma; Pseudomyxoma Peritonei; Rare Disorder; Scrotal Squamous Cell Carcinoma; Seminal Vesicle Adenocarcinoma; Seminoma; Serous Cystadenocarcinoma; Small Intestinal Adenocarcinoma; Small Intestinal Squamous Cell Carcinoma; Solid Neoplasm; Spindle Cell Neoplasm; Squamous Cell Carcinoma of the Penis; Teratoma With Somatic-Type Malignancy; Testicular Non-Seminomatous Germ Cell Tumor; Thyroid Gland Carcinoma; Tracheal Carcinoma; Transitional Cell Carcinoma; Ureter Adenocarcinoma; Ureter Squamous Cell Carcinoma; Urethral Adenocarcinoma; Urethral Squamous Cell Carcinoma; Vaginal Adenocarcinoma; Vaginal Squamous Cell Carcinoma, Not Otherwise Specified; Vulvar Carcinoma
Interventions: Procedure: Biospecimen Collection; Biological: Ipilimumab; Biological: Nivolumab
Sponsor: National Cancer Institute (NCI)
Recruiting
Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer
NCT02744092
Conditions: Cancer; Venous Thromboembolism; Deep Vein Thrombosis (DVT); Pulmonary Embolism (PE); Blood Clot
Interventions: Drug: Rivaroxaban; Drug: Apixaban; Drug: Edoxaban; Drug: Dabigatran; Drug: Warfarin; Drug: Dalteparin; Drug: Enoxaparin; Drug: Fondaparinux
Sponsors: Alliance Foundation Trials, LLC.; Patient-Centered Outcomes Research Institute
Recruiting
S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
NCT02562716
Conditions: Pancreatic Adenocarcinoma; Resectable Pancreatic Carcinoma
Interventions: Drug: Fluorouracil; Drug: Gemcitabine Hydrochloride; Drug: Irinotecan Hydrochloride; Drug: Oxaliplatin; Drug: Paclitaxel Albumin-Stabilized Nanoparticle Formulation; Procedure: Pancreatectomy
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer
NCT02488967
Conditions: Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma
Interventions: Drug: Carboplatin; Drug: Cyclophosphamide; Drug: Doxorubicin Hydrochloride; Other: Laboratory Biomarker Analysis; Drug: Paclitaxel
Sponsors: NRG Oncology; National Cancer Institute (NCI)
Recruiting
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
NCT02201992
Conditions: ALK Gene Rearrangement; ALK Gene Translocation; ALK Positive; Stage IB Non-Small Cell Lung Carcinoma AJCC v7; Stage II Non-Small Cell Lung Cancer AJCC v7; Stage IIA Non-Small Cell Lung Carcinoma AJCC v7; Stage IIB Non-Small Cell Lung Carcinoma AJCC v7; Stage IIIA Non-Small Cell Lung Cancer AJCC v7
Interventions: Other: Clinical Observation; Drug: Crizotinib; Other: Laboratory Biomarker Analysis
Sponsors: ECOG-ACRIN Cancer Research Group; National Cancer Institute (NCI)
Recruiting
Genetic Testing in Screening Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
NCT02194738
Conditions: Lung Adenocarcinoma; Lung Large Cell Carcinoma; Stage IB Lung Non-Small Cell Carcinoma AJCC v7; Stage IB Lung Squamous Cell Carcinoma AJCC v7; Stage II Lung Non-Small Cell Cancer AJCC v7; Stage II Lung Squamous Cell Carcinoma AJCC v7; Stage IIA Lung Non-Small Cell Carcinoma AJCC v7; Stage IIA Lung Squamous Cell Carcinoma AJCC v7; Stage IIB Lung Non-Small Cell Carcinoma AJCC v7; Stage IIB Lung Squamous Cell Carcinoma AJCC v7; Stage IIIA Lung Non-Small Cell Cancer AJCC v7; Stage IIIA Lung Squamous Cell Carcinoma AJCC v7
Interventions: Other: Clinical Observation; Drug: Crizotinib; Other: Cytology Specimen Collection Procedure; Drug: Erlotinib Hydrochloride; Biological: Nivolumab; Other: Placebo
Sponsor: National Cancer Institute (NCI)
Recruiting
Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)
NCT02193282
Conditions: ALK Gene Rearrangement; EGFR Exon 19 Deletion Mutation; EGFR NP_005219.2:p.L858R; Stage IB Lung Non-Small Cell Carcinoma AJCC v7; Stage II Lung Non-Small Cell Cancer AJCC v7; Stage IIA Lung Non-Small Cell Carcinoma AJCC v7; Stage IIB Lung Non-Small Cell Carcinoma AJCC v7; Stage IIIA Lung Non-Small Cell Cancer AJCC v7
Interventions: Other: Clinical Observation; Drug: Erlotinib Hydrochloride; Other: Laboratory Biomarker Analysis; Other: Placebo
Sponsor: National Cancer Institute (NCI)
Recruiting
Active Surveillance, Bleomycin, Carboplatin, Etoposide, or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
NCT03067181
Conditions: Adult Germ Cell Tumor; Childhood Extracranial Germ Cell Tumor; Childhood Germ Cell Tumor; Extragonadal Embryonal Carcinoma; Grade 2 Ovarian Teratoma; Malignant Germ Cell Tumor; Malignant Ovarian Teratoma; Stage I Ovarian Choriocarcinoma; Stage I Ovarian Embryonal Carcinoma AJCC v6 and v7; Stage I Ovarian Teratoma AJCC v6 and v7; Stage I Ovarian Yolk Sac Tumor AJCC v6 and v7; Stage I Testicular Choriocarcinoma AJCC v6 and v7; Stage I Testicular Embryonal Carcinoma AJCC v6 and v7; Stage I Testicular Yolk Sac Tumor AJCC v6 and v7; Stage II Ovarian Choriocarcinoma; Stage II Ovarian Embryonal Carcinoma AJCC v6 and v7; Stage II Ovarian Yolk Sac Tumor AJCC v6 and v7; Stage II Testicular Choriocarcinoma AJCC v6 and v7; Stage II Testicular Embryonal Carcinoma AJCC v6 and v7; Stage II Testicular Yolk Sac Tumor AJCC v6 and v7; Stage III Ovarian Choriocarcinoma; Stage III Ovarian Embryonal Carcinoma AJCC v6 and v7; Stage III Ovarian Yolk Sac Tumor AJCC v6 and v7; Stage III Testicular Choriocarcinoma AJCC v6 and v7; Stage III Testicular Embryonal Carcinoma AJCC v6 and v7; Stage III Testicular Yolk Sac Tumor AJCC v6 and v7; Stage IV Ovarian Choriocarcinoma; Stage IV Ovarian Embryonal Carcinoma AJCC v6 and v7; Stage IV Ovarian Yolk Sac Tumor AJCC v6 and v7; Testicular Mixed Choriocarcinoma and Embryonal Carcinoma; Testicular Mixed Choriocarcinoma and Teratoma; Testicular Mixed Choriocarcinoma and Yolk Sac Tumor
Interventions: Other: Best Practice; Drug: Bleomycin; Biological: Bleomycin Sulfate; Drug: Carboplatin; Drug: Cisplatin; Drug: Etoposide; Drug: Etoposide Phosphate; Other: Laboratory Biomarker Analysis; Other: Pharmacogenomic Study; Other: Quality-of-Life Assessment; Other: Questionnaire Administration
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting
Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma
NCT02567435
Conditions: Alveolar Rhabdomyosarcoma; Botryoid-Type Embryonal Rhabdomyosarcoma; Embryonal Rhabdomyosarcoma; Rhabdomyosarcoma; Sclerosing Rhabdomyosarcoma; Spindle Cell Rhabdomyosarcoma; Untreated Childhood Rhabdomyosarcoma
Interventions: Drug: Cyclophosphamide; Biological: Dactinomycin; Drug: Irinotecan Hydrochloride; Other: Laboratory Biomarker Analysis; Other: Questionnaire Administration; Radiation: Radiation Therapy; Drug: Temsirolimus; Drug: Vincristine Sulfate; Drug: Vinorelbine
Sponsor: National Cancer Institute (NCI)
Recruiting
Psoriasis Longitudinal Assessment and Registry (PSOLAR)
NCT00508547
Conditions: Psoriasis; Arthritis, Psoriatic
Interventions: Biological: Ustekinumab; Biological: Biological therapies other than infliximab, ustekinumab and guselkumab; Drug: Conventional systemic agents; Biological: Infliximab; Biological: Guselkumab
Sponsor: Janssen Scientific Affairs, LLC
Recruiting
Dysport in Vulvodynia Phase II Study
NCT03598777
Condition: Vulvodynia
Interventions: Biological: Botulinum toxin type A; Drug: Placebo
Sponsor: Ipsen
Recruiting
A Phase Ib Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of Avelumab in Combination With M9241(NHS-IL12) (JAVELIN IL-12)
NCT02994953
Condition: Advanced Solid Tumors
Interventions: Drug: Avelumab; Drug: NHS-IL12; Drug: Avelumab (Once weekly); Drug: NHS-IL12 (MTD); Drug: Avelumab (Expansion cohort)
Sponsors: EMD Serono Research & Development Institute, Inc.; Merck KGaA, Darmstadt, Germany
Recruiting
A Study to Assess the Safety, Tolerability and Efficacy of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
NCT03598790
Conditions: Chronic Plaque Psoriasis; Moderate to Severe Chronic Plaque Psoriasis
Intervention: Drug: Bimekizumab
Sponsor: UCB Biopharma S.P.R.L.
Recruiting
A Study to Assess the Safety and Efficacy of ZPL389 in Patients With Moderate to Severe Atopic Dermatitis
NCT03517566
Condition: Atopic Dermatitis
Interventions: Drug: Placebo; Drug: ZPL389
Sponsor: Novartis Pharmaceuticals
Recruiting
A Study of Tofacitinib in Patients With Ulcerative Colitis in Stable Remission
NCT03281304
Condition: Ulcerative Colitis
Interventions: Drug: CP-690,500 5 mg; Drug: CP-690,550 10 mg
Sponsor: Pfizer
Recruiting
A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas
NCT03893682
Conditions: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Non-Hodgkin's Lymphoma
Intervention: Drug: CG-806
Sponsor: Aptose Biosciences Inc.
Recruiting
M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC)
NCT03631706
Condition: Non-small Cell Lung Cancer
Interventions: Drug: M7824; Drug: Pembrolizumab
Sponsors: EMD Serono Research & Development Institute, Inc.; Merck KGaA, Darmstadt, Germany
Recruiting
A Study to Confirm Safety and Efficacy of BAN2401 in Participants With Early Alzheimer's Disease
NCT03887455
Condition: Early Alzheimer's Disease
Interventions: Drug: BAN2401; Drug: Placebo
Sponsors: Eisai Inc.; Biogen
Recruiting
Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)
NCT03971474
Conditions: Recurrent Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8
Interventions: Drug: Docetaxel; Drug: Gemcitabine; Drug: Gemcitabine Hydrochloride; Biological: Pembrolizumab; Drug: Pemetrexed; Drug: Pemetrexed Disodium; Biological: Ramucirumab
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting
Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH)
NCT03902080
Condition: Overactive Bladder
Interventions: Drug: Vibegron; Drug: Placebo
Sponsor: Urovant Sciences GmbH
Recruiting
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
NCT03851445
Condition: Previously Treated Non-Small Cell Lung Cancer
Intervention: Drug: Screening Platform
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting
Study to Evaluate the Efficacy and Safety of Vibegron Administered Orally for 12 Weeks to Women With Irritable Bowel Syndrome
NCT03806127
Condition: Irritable Bowel Syndrome
Interventions: Drug: Vibegron; Drug: Placebo
Sponsor: Urovant Sciences GmbH
Recruiting
Diabetic Gastroparesis Study 05
NCT03786380
Condition: Gastroparesis
Intervention: Drug: Relamorelin 10 μg
Sponsor: Allergan
Recruiting
A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy
NCT03762850
Condition: Immunoglobulin A Nephropathy
Interventions: Drug: sparsentan; Drug: irbesartan
Sponsor: Retrophin, Inc.
Recruiting
A Study to Assess Efficacy and Safety of SER‑287 in Adults With Active Mild-to-Moderate Ulcerative Colitis
NCT03759041
Condition: Ulcerative Colitis
Interventions: Drug: Vancomycin Pre-Treatment; Drug: Placebo for Vancomycin Pre-Treatment; Drug: SER-287; Drug: Placebo for SER-287
Sponsor: Seres Therapeutics, Inc.
Recruiting
Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
NCT03723928
Conditions: Anatomic Stage IV Breast Cancer AJCC v8; Estrogen Receptor Positive; HER2/Neu Negative; Progesterone Receptor Positive; Prognostic Stage IV Breast Cancer AJCC v8; Elevated CA15-3 or CEA or CA27-29
Interventions: Other: Usual care disease monitoring; Other: Serum Tumor Marker directed disease monitoring; Other: Quality-of-Life Assessment; Other: Anxiety Questionnaire Administration
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting
Ibrutinib and Obinutuzumab With or Without Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia
NCT03701282
Conditions: CCND1/IGHG1 Fusion Negative; Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; t(11;14) Negative
Interventions: Drug: Ibrutinib; Biological: Obinutuzumab; Other: Quality-of-Life Assessment; Drug: Venetoclax
Sponsor: National Cancer Institute (NCI)
Recruiting
Study to Assess the Long Term Safety and Tolerability of ACT-541468 in Adult and Elderly Subjects Suffering From Difficulties to Sleep
NCT03679884
Condition: Insomnia Disorder
Interventions: Drug: ACT-541468 10 mg; Drug: ACT-541468 25 mg; Drug: ACT-541468 50 mg; Drug: Placebo
Sponsor: Idorsia Pharmaceuticals Ltd.
Recruiting
A Cariprazine Study in the Prevention of Relapse in Bipolar I Disorder Patients Whose Current Episode is Manic or Depressive, With or Without Mixed Features
NCT03573297
Conditions: Bipolar I Disorder; Mania; Depression
Interventions: Drug: Cariprazine; Drug: Placebo
Sponsor: Forest Laboratories
Recruiting
A Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors
NCT03561090
Condition: Gastroesophageal Reflux Disease (GERD)
Interventions: Drug: IW-3718; Drug: placebo
Sponsor: Ironwood Pharmaceuticals, Inc.
Recruiting
Study to Evaluate Efficacy and Safety of Benralizumab in Reducing Oral Corticosteroid Use in Adult Patients With Severe Asthma
NCT03557307
Condition: Asthma
Intervention: Biological: Benralizumab
Sponsor: AstraZeneca
Recruiting
A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver Fibrosis
NCT03486899
Conditions: Liver Fibrosis; Nonalcoholic Fatty Liver Disease (NAFLD); Nonalcoholic Steatohepatitis
Interventions: Drug: BMS-986036; Other: Placebo
Sponsor: Bristol-Myers Squibb
Recruiting
Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 Status
NCT03457896
Condition: Metastatic Colorectal Cancer
Interventions: Drug: Trastuzumab; Drug: Cetuximab; Drug: Neratinib; Diagnostic Test: Guardant360 Diagnostic Test
Sponsors: NSABP Foundation Inc; Puma Biotechnology, Inc.
Recruiting
A Study of Baricitinib (LY3009104) in Adult Participants With Moderate to Severe Atopic Dermatitis
NCT03435081
Condition: Atopic Dermatitis
Interventions: Drug: Baricitinib; Drug: Placebo
Sponsors: Eli Lilly and Company; Incyte Corporation
Recruiting
A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 04
NCT03383146
Conditions: Gastroparesis; Diabetes Mellitus
Interventions: Drug: Relamorelin; Drug: Placebo
Sponsor: Allergan
Recruiting
A Study of the Efficacy and Safety of Upadacitnib (ABT-494) in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Conventional and/or Biologic Therapies
NCT03345849
Condition: Crohn's Disease
Interventions: Drug: Upadacitinib; Drug: Placebo for Upadacitinib
Sponsor: AbbVie
Recruiting
A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy
NCT03345836
Condition: Crohn's Disease
Interventions: Other: Matching placebo for upadacitinib; Drug: upadacitinib
Sponsor: AbbVie
Recruiting
BOTOX® Intravesical Instillation in Participants With Overactive Bladder and Urinary Incontinence
NCT03320850
Conditions: Urinary Incontinence; Overactive Bladder With Urinary Incontinence
Interventions: Drug: OnabotulinumtoxinA and Hydrogel admixture; Drug: Placebo and Hydrogel admixture
Sponsor: Allergan
Recruiting
A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis
NCT03285308
Conditions: Gastroparesis; Diabetes Mellitus
Interventions: Drug: Relamorelin; Drug: Placebo
Sponsor: Allergan
Recruiting
Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo
NCT03281954
Condition: Triple Negative Breast Cancer
Interventions: Drug: Placebo; Drug: Atezolizumab
Sponsors: NSABP Foundation Inc; Genentech, Inc.; Hoffmann-La Roche
Recruiting
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
NCT03269669
Conditions: Grade 1 Follicular Lymphoma; Grade 2 Follicular Lymphoma; Grade 3a Follicular Lymphoma; Recurrent Follicular Lymphoma; Refractory Follicular Lymphoma
Interventions: Drug: Bendamustine; Drug: Cyclophosphamide; Drug: Doxorubicin; Drug: Doxorubicin Hydrochloride; Drug: Lenalidomide; Biological: Obinutuzumab; Drug: Prednisone; Drug: Umbralisib; Drug: Vincristine; Drug: Vincristine Sulfate
Sponsor: National Cancer Institute (NCI)
Recruiting
Pembrolizumab in Treating Patients With Locally Advanced Bladder Cancer
NCT03244384
Conditions: Stage II Bladder Urothelial Carcinoma AJCC v6 and v7; Stage III Bladder Urothelial Carcinoma AJCC v6 and v7
Interventions: Other: Clinical Observation; Other: Laboratory Biomarker Analysis; Biological: Pembrolizumab; Other: Pharmacological Study; Other: Quality-of-Life Assessment; Other: Questionnaire Administration
Sponsor: National Cancer Institute (NCI)
Recruiting
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
NCT03233711
Conditions: Anal Basaloid Carcinoma; Anal Canal Cloacogenic Carcinoma; Anal Margin Squamous Cell Carcinoma; Stage IIB Anal Cancer AJCC v8; Stage IIIA Anal Cancer AJCC v8; Stage IIIB Anal Cancer AJCC v8; Stage IIIC Anal Cancer AJCC v8
Interventions: Biological: Nivolumab; Other: Patient Observation
Sponsors: National Cancer Institute (NCI); Canadian Cancer Trials Group
Recruiting
Extension Study of Pimavanserin for the Adjunctive Treatment of Schizophrenia
NCT03121586
Condition: Schizophrenia
Intervention: Drug: Pimavanserin
Sponsor: ACADIA Pharmaceuticals Inc.
Recruiting
MILD® Percutaneous Image-Guided Lumbar Decompression: A Medicare Claims Study
NCT03072927
Condition: Lumbar Spinal Stenosis
Intervention: Device: MILD
Sponsor: Vertos Medical, Inc.
Recruiting
A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer
NCT03009981
Condition: Prostate Cancer
Interventions: Drug: Apalutamide; Drug: LHRH Analogue; Drug: Abiraterone Acetate; Drug: Prednisone
Sponsors: Alliance Foundation Trials, LLC.; Janssen Research & Development, LLC
Recruiting
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
NCT02997228
Conditions: Colorectal Adenocarcinoma; Mismatch Repair Deficiency; Stage IV Colorectal Cancer AJCC v7; Stage IVA Colorectal Cancer AJCC v7; Stage IVB Colorectal Cancer AJCC v7
Interventions: Drug: Atezolizumab; Biological: Bevacizumab; Drug: Fluorouracil; Drug: Leucovorin Calcium; Drug: Oxaliplatin; Other: Quality-of-Life Assessment; Other: Questionnaire Administration
Sponsors: National Cancer Institute (NCI); NRG Oncology
Recruiting
Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer
NCT02954874
Conditions: Estrogen Receptor Negative; HER2/Neu Negative; Invasive Breast Carcinoma; Progesterone Receptor Negative; Stage 0 Breast Cancer AJCC v6 and v7; Stage I Breast Cancer AJCC v7; Stage IA Breast Cancer AJCC v7; Stage IB Breast Cancer AJCC v7; Stage II Breast Cancer AJCC v6 and v7; Stage IIA Breast Cancer AJCC v6 and v7; Stage IIB Breast Cancer AJCC v6 and v7; Stage III Breast Cancer AJCC v7; Stage IIIA Breast Cancer AJCC v7; Stage IIIB Breast Cancer AJCC v7; Stage IIIC Breast Cancer AJCC v7; Triple-Negative Breast Carcinoma
Interventions: Other: Laboratory Biomarker Analysis; Other: Patient Observation; Biological: Pembrolizumab; Other: Quality-of-Life Assessment; Other: Questionnaire Administration; Radiation: Radiation Therapy
Sponsor: National Cancer Institute (NCI)
Recruiting
A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors (Study #1)
NCT02163759
Condition: Ulcerative Colitis
Interventions: Drug: Adalimumab; Other: Adalimumab Placebo; Drug: Etrolizumab; Other: Etrolizumab Placebo
Sponsor: Hoffmann-La Roche
Recruiting
Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
NCT02912559
Conditions: Colon Adenocarcinoma; DNA Repair Disorder; Lynch Syndrome; Stage III Colon Cancer AJCC v7; Stage IIIA Colon Cancer AJCC v7; Stage IIIB Colon Cancer AJCC v7; Stage IIIC Colon Cancer AJCC v7
Interventions: Drug: Atezolizumab; Drug: Fluorouracil; Other: Laboratory Biomarker Analysis; Drug: Leucovorin Calcium; Drug: Oxaliplatin; Other: Quality-of-Life Assessment
Sponsor: National Cancer Institute (NCI)
Recruiting
Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)
NCT02876835
Condition: Anaemia
Interventions: Drug: Daprodustat; Drug: Darbepoetin alfa; Drug: Placebo; Drug: Iron Therapy
Sponsor: GlaxoSmithKline
Recruiting
Study of Safety and Efficacy of Tropifexor (LJN452) in Patients With Non-alcoholic Steatohepatitis (NASH)
NCT02855164
Condition: Non-alcoholic Steatohepatitis (NASH)
Interventions: Drug: Tropifexor (LJN452); Drug: Placebo
Sponsor: Novartis Pharmaceuticals
Recruiting
A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression
NCT02782104
Condition: Depressive Disorder, Treatment-Resistant
Intervention: Drug: Esketamine Nasal Spray
Sponsor: Janssen Research & Development, LLC
Recruiting
Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)
NCT02704403
Condition: Nonalcoholic Steatohepatitis (NASH) With Fibrosis
Interventions: Drug: Elafibranor; Drug: Placebo
Sponsor: Genfit
Recruiting
Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)
NCT02595944
Conditions: Stage IB Lung Non-Small Cell Carcinoma AJCC v7; Stage II Lung Non-Small Cell Cancer AJCC v7; Stage IIA Lung Non-Small Cell Carcinoma AJCC v7; Stage IIB Lung Non-Small Cell Carcinoma AJCC v7; Stage IIIA Lung Non-Small Cell Cancer AJCC v7
Intervention: Biological: Nivolumab
Sponsor: National Cancer Institute (NCI)
Recruiting
A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)
NCT02554812
Condition: Advanced Cancer
Interventions: Drug: Avelumab; Drug: Utomilumab; Drug: PF-04518600; Drug: PD 0360324; Drug: CMP-001
Sponsor: Pfizer
Recruiting
Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
NCT02446132
Condition: Agitation in Patients With Dementia of the Alzheimer's Type
Intervention: Drug: AVP-786
Sponsor: Avanir Pharmaceuticals
Recruiting
Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma
NCT02224781
Conditions: BRAF NP_004324.2:p.V600X; Metastatic Melanoma; Progressive Disease; Recurrent Melanoma; Stage III Cutaneous Melanoma AJCC v7; Stage IIIA Cutaneous Melanoma AJCC v7; Stage IIIB Cutaneous Melanoma AJCC v7; Stage IIIC Cutaneous Melanoma AJCC v7; Stage IV Cutaneous Melanoma AJCC v6 and v7; Unresectable Cutaneous Melanoma
Interventions: Drug: Dabrafenib; Drug: Dabrafenib Mesylate; Biological: Ipilimumab; Biological: Nivolumab; Other: Quality-of-Life Assessment; Drug: Trametinib; Drug: Trametinib Dimethyl Sulfoxide
Sponsor: National Cancer Institute (NCI)
Recruiting
Evaluation of Efficacy, Safety and Tolerability of VeraCept IUD
NCT03633799
Condition: Women at Risk for Pregnancy
Intervention: Drug: VeraCept
Sponsors: Sebela Pharmaceuticals Inc.; Synteract, Inc.
Recruiting
Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy
NCT01901094
Conditions: Stage II Breast Cancer; Stage IIIA Breast Cancer
Interventions: Procedure: Axillary Lymph Node Dissection (ALND); Radiation: Nodal Radiation Therapy; Radiation: Axillary Radiation Therapy
Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI); Canadian Cancer Trials Group
Recruiting
A Trial to Describe the Immunogenicity and Safety of 2 Doses of Bivalent rLP2086 (Trumenba) and a Pentavalent Meningococcal Vaccine in Healthy Subjects >=10 to <26 Years of Age.
NCT03135834
Condition: Meningococcal Vaccine
Interventions: Biological: MenABCWY; Biological: Saline; Biological: rLP2086; Biological: MenACWY-CRM
Sponsor: Pfizer
Recruiting
A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)
NCT01848561
Condition: Ulcerative Colitis (UC)
Intervention:
Sponsor: AbbVie
Recruiting
Cancer Care Delivery in Adolescent and Young Adult Patients With Acute Lymphoblastic Leukemia
NCT03204916
Condition: Acute Lymphoblastic Leukemia
Interventions: Other: Medical Chart Review; Other: Questionnaire Administration
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
NCT03155620
Conditions: Advanced Malignant Solid Neoplasm; Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma; Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma; Childhood Langerhans Cell Histiocytosis; Histiocytic Sarcoma; Juvenile Xanthogranuloma; Malignant Glioma; Recurrent Central Nervous System Neoplasm; Recurrent Childhood Ependymoma; Recurrent Childhood Malignant Germ Cell Tumor; Recurrent Childhood Medulloblastoma; Recurrent Childhood Non-Hodgkin Lymphoma; Recurrent Childhood Rhabdomyosarcoma; Recurrent Childhood Soft Tissue Sarcoma; Recurrent Ewing Sarcoma; Recurrent Glioma; Recurrent Hepatoblastoma; Recurrent Langerhans Cell Histiocytosis; Recurrent Malignant Solid Neoplasm; Recurrent Neuroblastoma; Recurrent Osteosarcoma; Recurrent Peripheral Primitive Neuroectodermal Tumor; Recurrent Rhabdoid Tumor; Refractory Central Nervous System Neoplasm; Refractory Childhood Malignant Germ Cell Tumor; Refractory Ewing Sarcoma; Refractory Glioma; Refractory Hepatoblastoma; Refractory Langerhans Cell Histiocytosis; Refractory Malignant Solid Neoplasm; Refractory Medulloblastoma; Refractory Neuroblastoma; Refractory Non-Hodgkin Lymphoma; Refractory Osteosarcoma; Refractory Peripheral Primitive Neuroectodermal Tumor; Refractory Rhabdoid Tumor; Refractory Rhabdomyosarcoma; Rhabdoid Tumor; Stage III Osteosarcoma AJCC v7; Stage III Soft Tissue Sarcoma AJCC v7; Stage IV Osteosarcoma AJCC v7; Stage IV Soft Tissue Sarcoma AJCC v7; Stage IVA Osteosarcoma AJCC v7; Stage IVB Osteosarcoma AJCC v7; Wilms Tumor
Interventions: Procedure: Biopsy; Procedure: Biospecimen Collection; Drug: Ensartinib; Drug: Erdafitinib; Other: Laboratory Biomarker Analysis; Drug: Larotrectinib; Procedure: Mutation Carrier Screening; Drug: Olaparib; Drug: Palbociclib; Other: Pharmacological Study; Drug: Samotolisib; Drug: Selumetinib Sulfate; Drug: Tazemetostat; Drug: Ulixertinib; Drug: Vemurafenib
Sponsor: National Cancer Institute (NCI)
Recruiting
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
NCT02867592
Conditions: Adrenal Cortex Carcinoma; Alveolar Soft Part Sarcoma; Central Nervous System Neoplasm; Childhood Clear Cell Sarcoma of Soft Parts; Clear Cell Sarcoma of Soft Tissue; Ewing Sarcoma; Hepatoblastoma; Hepatocellular Carcinoma; MITF Positive; Osteosarcoma; Recurrent Adrenal Cortex Carcinoma; Recurrent Alveolar Soft Part Sarcoma; Recurrent Ewing Sarcoma; Recurrent Hepatoblastoma; Recurrent Hepatocellular Carcinoma; Recurrent Malignant Central Nervous System Neoplasm; Recurrent Malignant Solid Neoplasm; Recurrent Osteosarcoma; Recurrent Renal Cell Carcinoma; Recurrent Rhabdomyosarcoma; Recurrent Soft Tissue Sarcoma; Recurrent Soft Tissue Sarcoma, Excluding Rhabdomyosarcoma; Recurrent Thyroid Gland Medullary Carcinoma; Refractory Ewing Sarcoma; Refractory Malignant Central Nervous System Neoplasm; Refractory Malignant Solid Neoplasm; Refractory Osteosarcoma; Refractory Rhabdomyosarcoma; Refractory Soft Tissue Sarcoma; Refractory Soft Tissue Sarcoma, Excluding Rhabdomyosarcoma; Renal Cell Carcinoma; Rhabdomyosarcoma; Soft Tissue Sarcoma, Excluding Rhabdomyosarcoma; Solid Neoplasm; Thyroid Gland Medullary Carcinoma; Wilms Tumor
Interventions: Drug: Cabozantinib; Drug: Cabozantinib S-malate; Other: Pharmacological Study
Sponsor: National Cancer Institute (NCI)
Recruiting
A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
NCT02723994
Condition: Leukemia
Interventions: Drug: Ruxolitinib; Drug: Asparaginase Erwinia Chrysanthemi; Drug: Cyclophosphamide; Drug: Cytarabine; Drug: Dexamethasone; Drug: Doxorubicin; Drug: Leucovorin Calcium; Drug: Mercaptopurine; Drug: Methotrexate; Drug: Pegaspargase; Drug: Prednisone; Drug: Thioguanine; Drug: Vincristine Sulfate
Sponsors: Incyte Corporation; Children's Oncology Group
Recruiting
S0820, Adenoma and Second Primary Prevention Trial
NCT01349881
Condition: Colorectal Neoplasms
Interventions: Drug: Eflornithine placebo & sulindac placebo; Drug: eflornithine & sulindac placebo; Drug: Eflornithine placebo & sulindac; Drug: Eflornithine plus sulindac
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI); Cancer Prevention Pharmaceuticals, Inc.
Recruiting
Project: Every Child for Younger Patients With Cancer
NCT02402244
Conditions: Central Nervous System Neoplasm; Childhood Immature Teratoma; Childhood Langerhans Cell Histiocytosis; Childhood Malignant Neoplasm; Childhood Mature Teratoma; Congenital Mesoblastic Nephroma; Desmoid-Type Fibromatosis; Lymphoproliferative Disorder; Myeloproliferative Neoplasm; Stromal Neoplasm
Interventions: Other: Cytology Specimen Collection Procedure; Other: Medical Chart Review
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting
Early Advanced Weight Bearing for Peri-articular Knee and Pilon Injuries
NCT03562364
Conditions: Distal Femur Fracture; Tibial Plateau Fracture; Distal Tibia Fracture; Pilon Fracture
Intervention: Other: AlterG anti-gravity treadmill
Sponsor: Major Extremity Trauma Research Consortium
Recruiting
Multi-center Study to Validate niPGT-A
NCT03520933
Conditions: Aneuploidy; Chromosome Abnormality; Infertility
Interventions: Diagnostic Test: PGT-A; Diagnostic Test: niPGT-A
Sponsor: Igenomix
Recruiting
Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma
NCT00904241
Conditions: Ganglioneuroblastoma; Localized Resectable Neuroblastoma; Localized Unresectable Neuroblastoma; Regional Neuroblastoma; Stage 4 Neuroblastoma; Stage 4S Neuroblastoma
Interventions: Other: Cytology Specimen Collection Procedure; Other: Laboratory Biomarker Analysis
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting
Study of Kidney Tumors in Younger Patients
NCT00898365
Conditions: Clear Cell Sarcoma of the Kidney; Congenital Mesoblastic Nephroma; Diffuse Hyperplastic Perilobar Nephroblastomatosis; Rhabdoid Tumor of the Kidney; Stage I Kidney Wilms Tumor; Stage I Renal Cell Cancer AJCC v6 and v7; Stage II Kidney Wilms Tumor; Stage II Renal Cell Cancer AJCC v7; Stage III Kidney Wilms Tumor; Stage III Renal Cell Cancer AJCC v7; Stage IV Kidney Wilms Tumor; Stage IV Renal Cell Cancer AJCC v7; Stage V Kidney Wilms Tumor
Interventions: Other: Cytology Specimen Collection Procedure; Other: Laboratory Biomarker Analysis
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting
A Study of ABI-H2158 in Healthy Volunteers and Patients With Chronic Hepatitis B
NCT03714152
Condition: Chronic Hepatitis B
Interventions: Drug: ABI-H2158; Drug: Placebo for ABI-H2158
Sponsor: Assembly Biosciences
Recruiting
Safety and Immunotherapeutic Activity of an Anti-PD-1 Antibody (Cemiplimab) in HIV-1-infected Participants on Suppressive cART
NCT03787095
Condition: HIV Infections
Interventions: Biological: Cemiplimab; Biological: Placebo
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); Regeneron Pharmaceuticals
Recruiting
Study of a Levonorgestrel 52 mg Intrauterine System for the Treatment of Heavy Menstrual Bleeding
NCT03642210
Condition: Menorrhagia
Intervention: Combination Product: Levonorgestrel 52 mg intrauterine system
Sponsor: Medicines360
Recruiting

Menu

Categories

Recent Listings

Post your clinical trial on JoinClinicalTrials.com

JoinClinicalTrials.com

Results

Post your clinical trial on JoinClinicalTrials.com

Popular Now